skip to main content

News Archive

Date: 12/06/2022
Principal investigator Arul Chinnaiyan, M.D., Ph.D., will lead a $4 million project that will employ a suite of cutting-edge drug development techniques to develop an effective inhibitor of MYC, a major driver of about 70% of all cancers, including prostate cancer.
Date: 11/23/2022
As cancers grow and potentially spread to new parts of the body, they often shed cells and DNA into the blood stream. DNA can be analyzed for both the amount of DNA present and whether any potential mutations exist that may aid providers in deciding on treatments. These tests, known as liquid biopsies, have become standard practice for certain types of cancer, especially those for which there are drugs that target distinct DNA mutations. Whether liquid biopsies could help providers understand which patients may do better than others, though, is unknown.
Date: 11/18/2022
As part of its Discovery Science grants program, the American Cancer Society has awarded Rogel Cancer Center researcher Anthony Scott, M.D., $792,000 to look at how genes associated with Lynch syndrome impact cancer developing.
Date: 11/08/2022
The death rate for women with metastatic breast cancer is linked to the number of chronic health conditions they have, according to a study by the University of Michigan in partnership with the Kaiser Permanente Southern California Department of Research & Evaluation.
Date: 10/25/2022
In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration (VA) medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.
Date: 10/24/2022
A new study, presented at the annual ASTRO meeting, finds that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs.
Date: 10/13/2022
An international team of researchers led by the University of Michigan Rogel Cancer Center received a collaborative grant from the National Cancer Institute with a goal of bringing new insights into leiomyosarcoma, a rare form of cancer that seemingly originates in smooth muscle. The grant, worth $12.3 million, is through the NCI’s SPORE, or Specialized Program of Research Excellence, which funds collaborative, interdisciplinary translational cancer research.
Date: 10/12/2022
Rogel Cancer Center faculty and trainees will lead 30 presentations, posters and moderated sessions at the American Society of Radiation Oncology annual meeting. This year’s meeting will be held in-person, virtually and on-demand.
Date: 10/05/2022
Friends, faculty and staff of the Rogel Cancer Center gathered amidst a rainbow of lights, ribbons and balloons on Sept. 23 to raise money for cancer research.
Date: 10/03/2022
Menthol cigarettes are designed to make it easier to start smoking and harder to quit. In Michigan, 40% of callers to the state’s Tobacco Quitline are menthol users. Now, a new partnership between the University of Michigan Rogel Cancer Center and the Quitline will develop and test strategies to help menthol users kick the habit.